Xumeler is adalimumab injection, the injection of this product needs to be evaluated according to the tuberculosis examination, viral infection examination and cardiac function test. 1. Tuberculosis examination: tuberculin skin test is needed before taking adalimumab, if it is active tuberculosis, this product should be prohibited; but if it is inactive tuberculosis or latent tuberculosis and the result of the examination is negative, it can be further weighed by the doctor. 2. Viral infection examination: mainly including hepatitis virus screening, HIV screening, etc. If the virus is found to be active according to the examination results, adalimumab should be prohibited; if the virus screening results are negative, no infection can be injected. 3. Cardiac function tests: such as echocardiography, mainly based on the examination to assess the presence or absence of heart failure, for mild heart failure need to be cautious use of this product, if belong to moderate or severe heart failure need to be prohibited. In the course of treatment should also be regularly reviewed, hemorrhagic heart failure need to stop using. The use of adalimumab should pay attention to related matters, if allergic to the components of the product, should be prohibited. If there are several of the above conditions to consult the doctor, and under the guidance of the doctor to use. During the use of the drug some patients may have headache, bleeding, skin itching and other adverse reactions. The use of this drug must follow the doctor’s instructions, not blindly use the drug on their own, so as not to cause adverse consequences.